Abstract
Several types of herbal preparations have been used as supplementary therapies for the treatment of progressive chronic kidney disease (CKD), but the scientific evidence for their use is scarce. The aim of the present study was to determine the effects of Astragalus membranaceus on renal outcome in patients with progressive CKD. The study population consisted of 35 patients with CKD stages 4 and 5 whose estimated glomerular filtration rate (eGFR) decreased over a 3-month period before the start of A membranaceus treatment despite the use of conventional therapy (from 14.6 ± 6.28 mL/min/1.73 m 2 to 11.6 ± 5.24; mean ± SD, p < 0.05). Similarly, the eGFR of 15 patients with CKD stage 4 decreased over the same period despite conventional therapy (from 20.8 ± 4.59 to 16.7 ± 4.17; r = −1.298; p < 0.05), but increased after the initial period of 3 months of supplementary treatment with A membranaceus (to 18.6 ± 5.67; r = 0.973; p < 0.05) and remained at that level at 6 months (17.8 ± 5.60) and 12 months (16.3 ± 5.89). However, in 20 patients with CKD stage 5, the beneficial effect of A membranaceus was limited to the first 3 months only (−3 months: 10.5 ± 2.7, baseline: 8.0 ± 2.75, 3 months: 8.4 ± 2.96, 6 months: 6.8 ± 2.45). A membranaceus had no significant effects on other laboratory parameters. Only seven patients (1 in stage 4 and 6 in stage 5) required dialysis within 12 months of A membranaceus treatment, whose eGFR at baseline was relatively low (7.4 ± 1.06). The results suggest that A membranaceus can maintain stable levels of eGFR and delay the initiation of renal replacement therapy in patients with progressive CKD stage 4. 至今已有數種草藥製劑被應用於進行性慢性腎病(CKD)的補充療法,然而此用途仍缺乏相關的科學理據。本研究旨在探討膜莢黃耆( Astragalus membranaceus )對進行性CKD患者的腎臟效應。研究對象為35位第4或5期CKD患者,即使在常規治療下(不包括 A membranaceus ),其腎絲球過濾率估算值(eGFR)仍在3個月內明顯下降(從14.6 ± 6.28 mL/min/1.73 m 2 至11.6 ± 5.24; mean ± SD, p < 0.05)。其中15人為第4期CKD患者,eGFR於該段期間明顯下降(從20.8 ± 4.59至16.7 ± 4.17; r = −1.298; p < 0.05),但在膜莢黃耆補充療法開始後3個月回升(至18.6 ± 5.67; r = 0.973; p < 0.05),並維持穩定於6個月(17.8 ± 5.60)及12個月(16.3 ± 5.89)。另外20位為第5期CKD患者,膜莢黃耆對其效益僅可見於首3個月(−3個月: 10.5 ± 2.7, 基線: 8.0 ± 2.75, 3個月: 8.4 ± 2.96, 6個月: 6.8 ± 2.45)。至於其他實驗室項目,膜莢黃耆並不具明顯效應。在膜莢黃耆的12個月治療期間,僅7人(第4期:1人;第5期:6人)需接受透析治療,其基線eGFR均偏低(7.4 ± 1.06)。因此,對於第4期進行性CKD患者,膜莢黃耆有助維持eGFR於穩定水平,並延遲腎臟替代療法的開始時間.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.